Table 2.
All‐cause mortality risk among cases of selected cancers
| All‐cause mortality by cancer site | WTC‐MMTP versus NYS‐non‐responders | WTC non‐MMTP versus NYS‐non‐responders |
|---|---|---|
| HR (95% CI) | HR (95% CI) | |
| (A) All‐cause mortality risk by cancer site: Follow‐up time starts at diagnosis date | ||
| Prostate | 0.62 (0.44, 0.88) | 0.92 (0.54, 1.55) |
| Lung and bronchus | 0.74 (0.56, 0.97) | 0.88 (0.60, 1.28) |
| Esophagus | 0.65 (0.36, 1.18) | 1.15 (0.55, 2.43) |
| Colon and rectum | 0.48 (0.31, 0.74) | 1.11 (0.60, 2.06) |
| Myeloma | 0.49 (0.22, 1.10) | 0.50 (0.16, 1.54) |
| Pancreas | 1.66 (1.15, 2.39) | 1.18 (0.61, 2.27) |
| Brain and other nervous system | 1.11 (0.70, 1.76) | 0.87 (0.42, 1.83) |
| Liver | 0.74 (0.44, 1.22) | 1.00 (0.50, 2.01) |
| Melanoma of the skin | 0.54 (0.27, 1.08) | 0.82 (0.20, 3.27) |
| Kidney and renal pelvis | 0.36 (0.16, 0.79) | 1.23 (0.51, 2.96) |
| (B) All‐cause mortality risk by cancer site: Follow‐up time starts on January 1, 2005 | ||
| Prostate | 0.59 (0.42, 0.84) | 0.88 (0.52, 1.49) |
| Lung | 0.59 (0.44, 0.78) | 0.76 (0.52, 1.10) |
| Esophagus | 0.60 (0.33, 1.09) | 1.81 (0.86, 3.80) |
| Colon and rectum | 0.50 (0.32, 0.76) | 1.10 (0.59, 2.05) |
| Myeloma | 0.49 (0.22, 1.10) | 0.48 (0.15, 1.48) |
| Pancreas | 1.10 (0.76, 1.58) | 2.31 (1.20, 4.44) |
| Brain and other nervous system | 1.07 (0.67, 1.71) | 0.97 (0.46, 2.04) |
| Liver | 0.73 (0.44, 1.21) | 2.25 (1.12, 4.50) |
| Melanoma of the skin | 0.52 (0.26, 1.05) | 0.90 (0.22, 3.60) |
| Kidney and renal pelvis | 0.37 (0.17, 0.82) | 1.40 (0.58, 3.38) |
Note: All models controlled for calendar year, age, race/ethnicity, sex (except prostate), and stage; models are restricted to participants aged 40 and older. Bold indicates p < 0.05.
Abbreviations: HR, hazard ratio; NYS‐non‐responders, all other cancer patients who were residents of the 11‐southernmost counties of New York State and were not included in one of the WTC‐responder cohorts; WTC‐MMTP, cancer patients enrolled in the World Trade Center Medical Monitoring and Treatment Program; WTC‐non‐MMTP, WTC‐exposed cancer patients who were NOT enrolled in the WTC‐MMTP.